Oculis (NASDAQ:OCS) Stock Rating Reaffirmed by HC Wainwright

Oculis (NASDAQ:OCS)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $30.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 88.09% from the company’s previous close.

Oculis Stock Down 1.9 %

Oculis stock opened at $15.95 on Wednesday. The firm has a market capitalization of $646.04 million, a P/E ratio of -8.96 and a beta of 0.30. The stock’s fifty day simple moving average is $12.89 and its 200-day simple moving average is $12.20. Oculis has a twelve month low of $9.05 and a twelve month high of $16.70. The company has a current ratio of 5.27, a quick ratio of 5.27 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.13). The company had revenue of $0.27 million for the quarter, compared to analysts’ expectations of $0.28 million. Oculis had a negative return on equity of 61.33% and a negative net margin of 7,679.05%. As a group, equities analysts expect that Oculis will post -2.19 earnings per share for the current fiscal year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.